Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11026
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBellomo, Rinaldoen
dc.contributor.authorProwle, John Ren
dc.contributor.authorEcheverri, Jorge Een
dc.date.accessioned2015-05-16T00:36:18Z-
dc.date.available2015-05-16T00:36:18Z-
dc.date.issued2010-04-20en
dc.identifier.citationContributions To Nephrology 2010; 164(): 153-63en
dc.identifier.govdoc20428001en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11026en
dc.description.abstractDiuretics are the most commonly used drugs to treat clinically diagnosed fluid overload in patients with heart failure. There is no conclusive evidence that they alter major outcomes such as survival to hospital discharge or time in hospital compared to other therapies. However, they demonstrably achieve fluid removal in the majority of patients, restore dry body weight, improve the breathlessness of pulmonary edema and are unlikely to be subjected to a large double-blind randomized controlled trial in this setting because of lack of equipoise. The effective and safe use of diuretics requires physiological understanding of the pharmacokinetics and pharmacodynamics of diuretic therapy, an appreciation of the clinical goals of diuretic therapy, the application of physiological targeting of dose, an understanding of the effects of hemodynamic impairment on their ability to achieve fluid removal, an appreciation of the effects of combinations of different diuretics in patients refractory to single agents and an understanding of the most common side effects of such therapy. The use of continuous infusions of loop diuretics, sometimes combined with carbonic anhydrase inhibitors and/or aldosterone antagonists and/or thiazide diuretics can prove particularly effective in patients with advanced heart failure. Such therapy often requires more intensive monitoring than available in medical wards. If diuretic therapy fails to achieve its clinical goals, ultrafiltration by semipermeable membranes is reliably effective in achieving targeted fluid removal. The combination of diuretic therapy and/or ultrafiltration can achieve volume control in essentially all patients with heart failure.en
dc.language.isoenen
dc.subject.otherAgeden
dc.subject.otherDiuretics.therapeutic useen
dc.subject.otherHeart Failure.drug therapyen
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherPericardial Effusion.drug therapyen
dc.subject.otherPleural Effusion.drug therapyen
dc.subject.otherPostoperative Hemorrhage.drug therapyen
dc.subject.otherRheumatic Heart Disease.drug therapy.surgeryen
dc.subject.otherWater-Electrolyte Imbalance.drug therapyen
dc.titleDiuretic therapy in fluid-overloaded and heart failure patients.en
dc.typeJournal Articleen
dc.identifier.journaltitleContributions to nephrologyen
dc.identifier.affiliationDepartment of Intensive Care, Austin Health, Heidelberg, Victoria, Australia, Australiaen
dc.identifier.doi10.1159/000313728en
dc.description.pages153-63en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/20428001en
dc.type.austinJournal Articleen
local.name.researcherBellomo, Rinaldo
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptIntensive Care-
crisitem.author.deptData Analytics Research and Evaluation (DARE) Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Jun 14, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.